MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2016 International Congress

    Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III

    B.L. Greco, T. Simuni, J. Lowell, K.C. Hodgeman, S. Sharma, C.A. Marshall, J. Denmark, W. Galpern, J.L. Goudreau, C. Meuiner, C. Sia, C.A. Thomas, D. Young, K.M. Biglan (Rochester, NY, USA)

    Objective: To review a successful multi-modal recruitment strategy in a clinical trial of early untreated PD patients. Background: STEADY-PD III is a multicenter NINDS funded…
  • 2016 International Congress

    Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein

    Z. Alexopoulou, J. Lang, R. Perrett, H.T. Kim, A.L. Goldberg, O. Ansorge, T.A. Fulga, G.K. Tofaris (Oxford, United Kingdom)

    Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…
  • 2016 International Congress

    Risk factors for premature withdraw from the LS-1 PD study

    J.Y. Fang, S. Luo, M. Huang, R.B. Dewey, R. Hauser, G. Chen (Nashville, TN, USA)

    Objective: To identify risk factors for premature withdrawal from a large, multi-center Parkinson's disease clinical trial of possible neuroprotection. Background: Premature withdrawal (PW) of subjects…
  • 2016 International Congress

    Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

    B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

    Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…
  • 2016 International Congress

    Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype

    I. Huertas Fernandez, S. Jesus, J.A. Lojo, F.J. Garcia Gomez, M. Caceres Redondo, J.M. Oropesa Ruiz, F. Carrillo, L. Vargas Gonzalez, J.F. Martin Rodriguez, P. Gomez Garre, D. Garcia Solis, P. Mir (Sevilla, Spain)

    Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…
  • 2016 International Congress

    A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity

    L.V. Kalia, K. Menezes, Y. Zhang, S. Ishikura, N. Tran, H. Chau, A.M. Lozano, S.K. Kalia, J.G. Culotti, S. Suo, W.S. Ryu (Toronto, ON, Canada)

    Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…
  • 2016 International Congress

    Sodium butyrate attenuates rotenone-induced neurodegeneration via enhancing autophagy and preventing α-synuclein aggregation

    L. Liu, C. Han, K. Ma, X. Xu, J. Huang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

    Objective: To investigate whether sodium butyrate (NaB) could enhance autophagy and thus exert a neuroprotective effect through the modulation of α-synuclein in animal models of…
  • 2016 International Congress

    Beneficial effect of L-theanine against 3-nitropropionic acid induced neurotoxicity in rats: Possible role of neurotransmitters and nitric oxide

    P. Kumar, S. Jamwal (Moga, India)

    Objective: The present study was intended to investigate the effect of L-theanine against 3-NP induced striatal toxicity. Background: L-theanine is unique amino acid which readily…
  • 2016 International Congress

    Piperine potentiates neuroprotective effect of curcumin in MPTP model of Parkinson’s disease in rats: Impact on neurochemical modulation

    S. Singh, P. Kumar (Moga, India)

    Objective: (1) Curcumin is well tolerated phenolic compound used for CNS disorder but problem is its low oral bioavailability and (2) Piperine is combined to…
  • 2016 International Congress

    Participation in cognitively-stimulating activities and computer use are associated with better cognitive performance in Parkinson’s disease independent from nigrostriatal dopaminergic and cortical cholinergic degenerations

    J.L.B. Bohnen, M.L.T.M. Muller, J.D.J. Haugen, N.I. Bohnen (Ann Arbor, MI, USA)

    Objective: To investigate the relationship between times spent with cognitively stimulating activities and cognitive functions in Parkinson's disease (PD) while accounting for the degree of…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley